CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 31, 2023

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions
Next-Generation-Sequencing
Interventions
GENETIC

Molecular genetic diagnostic

With the help of modern, highly sensitive analysis methods (NGS), such as ultra-low high-throughput sequencing, even the smallest amounts of circulating cell-free nucleic acids in the blood can be detected. In the individual course of therapy, the changes in concentration of the tumor-specific variants can thus be continuously monitored and appropriate therapy decisions can be made. The presence of minimal residual diseases and the development of resistance mutations can also be examined using this technique.

All Listed Sponsors
collaborator

German Consortium for Translational Cancer Research

OTHER

lead

University Hospital Tuebingen

OTHER

NCT05871593 - CIRculating Cell-free nUcLeic Acids in Cancer Therapy Monitoring -01 | Biotech Hunter | Biotech Hunter